Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALTEROLA BIOTECH, INC.

(ABTI)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ALTEROLA BIOTECH INC. : Change in Directors or Principal Officers (form 8-K)

10/05/2021 | 05:11pm EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 28, 2021, the board of directors and shareholders removed Larson Elsmore as Vice Chairman, CFO, Secretary and Director. On the same date, the board of directors appointed Timothy Rogers as Interim CFO and Seamus McAuley as the company's Secretary.

Also on September 28, 2021, the board of directors appointed Hunter Land to serve as Director and Vice President of Translational Research.

Also on September 28, 2021, the board of directors resolved to terminate all existing advisory boards of the company and to establish an Audit and Compliance Committee, with Ning Qu to serve as Chairperson.

The board of directors has also adopted a charter for the Audit and Compliance Committee, which is attached as Exhibit 99.1, and incorporated herein by reference.

Timothy Paul Rogers - Age 57

The employment history for Mr. Rogers is contained in Form 10-KT filed with the SEC on June 9, 2021.




Seamus McAuley - Age 45



The employment history for Mr. McAuley is contained in Form 10-KT filed with the SEC on June 9, 2021.




Hunter Land - Age 37



Hunter Land has over 20 years of R&D expertise across 15 different indications, as well as 10 years of cannabinoid-focused research. As an expert in the field of cannabinoid science, he has developed a pipeline of discovery work on over 20 novel cannabinoids and terpenes. Previously, Hunter acted as the Sr. Scientific Director, Director of Cannabinoid Research, and scientific spokesperson at Canopy Growth Corporation. Most notably, Hunter co-established R&D for GW Pharmaceuticals within the US, where he authored multiple protocols in refractory epilepsy (Dravet Syndrome and Lennox-Gastaut Syndrome), Multiple Sclerosis, pain, and led the clinical development of Epidiolex® (FDA approved prescription CBD). Hunter acts as the Sr. Scientific Advisor for the National Hockey League Alumni Association in conjunction with NEEKA Brain Health, a board member of Veterinary Cannabis Society, and lectures at the University of Wisconsin. He has been a featured speaker at over 50 scientific conferences, a named inventor on 6 patent applications, and has over 20 publications.

Mr. Land has not had any direct or indirect interest in any transaction in the past two years involving the company.

© Edgar Online, source Glimpses

All news about ALTEROLA BIOTECH, INC.
11/16Alterola Biotech, Inc. signed an agreement to acquire Assets from C2 Wellness Corporati..
CI
11/15ALTEROLA BIOTECH INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
10/05ALTEROLA BIOTECH : Board Replaces Outgoing CFO Larson Elsmore With Timothy Rogers as Inter..
MT
10/05ALTEROLA BIOTECH INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/05Alterola Biotech, Inc. Announces Executive Changes
CI
10/05Alterola Biotech, Inc. Announces Executive Changes
CI
09/23Alterola Biotech, Inc. Confirms Appointment of Hunter Land to the Board
CI
08/19ALTEROLA BIOTECH : Management's Discussion and Analysis of Financial Condition and Results..
AQ
08/02ALTEROLA BIOTECH : acquires ABTI pharma ltd
AQ
06/21ALTEROLA BIOTECH INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -0,34 M - -
Net Debt 2021 0,03 M - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 244 M 244 M -
EV / Sales 2020
EV / Sales 2021 -
Nbr of Employees -
Free-Float 15,0%
Chart ALTEROLA BIOTECH, INC.
Duration : Period :
Alterola Biotech, Inc. Technical Analysis Chart | ABTI | US02152V1035 | MarketScreener
Income Statement Evolution
Managers and Directors
Seamus McAuley Chief Executive Officer & Secretary
Timothy Paul Rogers Chairman & Chief Financial Officer
Colin Stott Chief Operating Officer & Director
Dominic Schiller Director
Daniel S. Reshef Director
Sector and Competitors
1st jan.Capi. (M$)
ALTEROLA BIOTECH, INC.-0.03%244
GILEAD SCIENCES, INC.20.27%87 895
BIONTECH SE273.85%73 606
REGENERON PHARMACEUTICALS34.17%67 771
WUXI APPTEC CO., LTD.24.40%62 328
VERTEX PHARMACEUTICALS-21.20%47 352